3',4',5,7-Tetrahydroxy-Flavone, 3',4',5,7-Tetrahydroxyflavone, Luteolin, Luteoline
| Name | Luteolin | ||
| PubChem CID | 5280445 | ||
| Molecular Weight | 286.24g/mol | ||
| Synonyms |
3',4',5,7-Tetrahydroxy-Flavone, 3',4',5,7-Tetrahydroxyflavone, Luteolin, Luteoline |
||
| Formula | C₁₅H₁₀O₆ | ||
| SMILES | C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O | ||
| InChI | 1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H | ||
| InChIKey | IQPNAANSBPBGFQ-UHFFFAOYSA-N | ||
| CAS Number | 491-70-3 | ||
| ChEMBL ID | CHEMBL151 | ||
| ChEBI ID | CHEBI:15864 | ||
| Herb ID | HBIN033803 | ||
| Drug Bank ID | DB15584 | ||
| KEGG ID | C01514 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | PuGongYing | ||
| Use Part | Aerial parts | ||
| Habitat | China | ||
| Flavor | Bitter; Sweet | ||
| Meridian Tropism | Liver; Stomach | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Asterales
-->Family: Asteraceae
-->Genus: Taraxacum
-->Species: Taraxacum mongolicum
|
||
| Pair Name | Luteolin, Paclitaxel | |||
| Partner Name | Paclitaxel | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | CRIPTO | hsa6997 |
| Down-regulation | Expression | HMOX1 | hsa3162 | |
| Down-regulation | Expression | NFE2L2 | hsa4780 | |
| In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
| Result | These findings suggest that luteolin treatment significantly attenuated the hallmarks of breast cancer stemness by downregulating Nrf2-mediated expressions. Luteolin constitutes a potential agent for use in cancer stemness-targeted breast cancer treatments. | |||
| Pair Name | Luteolin, Lapatinib | |||
| Partner Name | Lapatinib | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Up-regulation | Expression | BCL2L11 | KEGG ID N.A. |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | FOXO3 | hsa2309 | |
| Down-regulation | Phosphorylation | FOXO3 | hsa2309 | |
| Up-regulation | Expression | GADD45A | hsa1647 | |
| Up-regulation | Expression | NQO1 | hsa1728 | |
| In Vitro Model | SK-BR-3 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0033 |
| BT-474 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0179 | |
| ZR-75-1 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0588 | |
| In Vivo Model | Mice were inoculated subcutaneously with 0.1 mL of cell suspension (ZR-75-1 and BT-474 cells). | |||
| Result | These data suggest that the combination of Lapatinib and luteolin may inhibit HER2 human breast cancer by significantly increasing the expression of FOXO3a and NQO1, two key genes in HER2 human breast cancer xenografts. | |||
| Pair Name | Luteolin, Erlotinib | |||
| Partner Name | Erlotinib | |||
| Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | BAD | hsa572 | |
| Down-regulation | Expression | BCL-xL | hsa598 | |
| Down-regulation | Phosphorylation | EGFR | hsa1956 | |
| Down-regulation | Phosphorylation | MTOR | hsa2475 | |
| Down-regulation | Phosphorylation | NFKB1 | hsa4790 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| In Vitro Model | U-251MG | Astrocytoma | Homo sapiens (Human) | CVCL_0021 |
| U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 | |
| Result | These findings suggest that combining luteolin with erlotinib offers a potential treatment strategy for glioblastoma multiforme IV. | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Oxaliplatin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | CCNA2 | hsa890 | |
| Down-regulation | Expression | CCNB1 | hsa891 | |
| Down-regulation | Expression | CD40LG | hsa959 | |
| Down-regulation | Expression | CDC25C | hsa995 | |
| Down-regulation | Expression | CDK1 | hsa983 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| In Vitro Model | MFC | Mouse gastric carcinoma | Mus musculus (Mouse) | CVCL_5J48 |
| Result | Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G2/M cell cycle arrest and apoptosis | |||
| Pair Name | Luteolin, TNF-related apoptosis inducing ligand | |||
| Partner Name | TNF-related apoptosis inducing ligand | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Mitochondrial fission and apoptosis | |||
| Gene Regulation | Up-regulation | Expression | DNM1L | hsa10059 |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Expression | TNFRSF10B | hsa8795 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 | |
| Result | TRAIL combined with luteolin could be as an effective chemotherapeutic strategy for NSCLC. | |||
| Pair Name | Luteolin, TNF-related apoptosis inducing ligand | |||
| Partner Name | TNF-related apoptosis inducing ligand | |||
| Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | CASP8 | hsa841 |
| Down-regulation | Expression | MIR301A | hsa407027 | |
| In Vitro Model | PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 |
| Result | Our findings unveil a critical biological function of miR-301-3p in regulating cell proliferation and elevating an antiproliferative effect of TRAIL on cancer cells. Our observation of miR-301-3p/caspase-8 relationship can also serve to clarify the role of miR-301-3p in other cancer types and related diseases. | |||
| Pair Name | Luteolin, Paclitaxel | |||
| Partner Name | Paclitaxel | |||
| Disease Info | [ICD-11: 2B70] | Esophageal cancer | Investigative | |
| Biological Phenomena | Inhibition-->Epithelial-mesenchymal transition | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Up-regulation | Expression | CDH1 | hsa999 | |
| Down-regulation | Expression | CDH2 | hsa1000 | |
| Up-regulation | Expression | CLDN1 | hsa9076 | |
| Up-regulation | Phosphorylation | MAP2K4 | hsa6416 | |
| Up-regulation | Phosphorylation | MAP3K5 | hsa4217 | |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Expression | PMAIP1 | hsa5366 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| Down-regulation | Expression | SIRT1 | hsa23411 | |
| Down-regulation | Expression | VIM | hsa7431 | |
| In Vitro Model | TE-1 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_1759 |
| Eca-109 | Esophageal squamous cell carcinoma | Homo sapiens (Human) | CVCL_6898 | |
| In Vivo Model | EC109 cells(3×10⁶) were suspended in 200μl saline and injected subcutane-ously into the right forelimb of each mouse. | |||
| Result | The molecular mechanism of inhibiting cell migration and EMT processes may be related to the inhibition of SIRT1, and the mechanism of apoptosis induction is associated with the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) pathway-mediated activation of mitochondrial apoptotic pathway. | |||
| Pair Name | Luteolin, Bortezomib | |||
| Partner Name | Bortezomib | |||
| Disease Info | [ICD-11: 2A83] | Multiple myeloma | Investigative | |
| Gene Regulation | Down-regulation | Expression | ALDH1A1 | hsa216 |
| Down-regulation | Phosphorylation | SMAD2 | hsa4087 | |
| Down-regulation | Expression | TGFBR1 | hsa7046 | |
| In Vitro Model | ANBL-6 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_5425 |
| ARP-1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_D523 | |
| KMS-11 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_2989 | |
| MM1.S | Plasma cell myeloma | Homo sapiens (Human) | CVCL_8792 | |
| RPMI-8226 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0014 | |
| In Vivo Model | Female BALB/c nude mice were subcutaneously inoculated in the flank with 5×10⁶ luciferase-labeled ARP1 cells in 200 μL of PBS. NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt (NCG) mice were subcutaneously inoculated in the flank with 1×107 luciferase-labeled ARP1-BR cells in 200 μL of PBS. | |||
| Result | Our findings suggested that LUT is a promising agent that manifests MMSCs to overcome BTZ resistance, alone or in combination with BTZ, and thus, is a potential therapeutic drug for the treatment of MM. | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Oxaliplatin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Down-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| Up-regulation | Expression | HMOX1 | hsa3162 | |
| Up-regulation | Activity | NFE2L2 | hsa4780 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| Result | Luteolin can induce p53-mediated apoptosis regardless of oxaliplatin treatment and may eliminate oxaliplatin-resistant p53-null colorectal cells | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Oxaliplatin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Expression | CYCS | hsa54205 | |
| In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
| Result | Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin through the Cyt c/caspase pathway | |||
| Pair Name | Luteolin, Erastin | |||
| Partner Name | Erastin | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Biological Phenomena | Induction-->Ferroptosis | |||
| Gene Regulation | Down-regulation | Expression | GPX4 | hsa2879 |
| Up-regulation | Expression | HIC1 | hsa3090 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| SW480 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0546 | |
| In Vivo Model | The mice were subjected to subcutaneously injection with HCT116 cells (5×10⁶, suspended in PBS) in each right flank, the mice were treated every 2 days for eight times. | |||
| Result | These results clearly demonstrated that luteolin acts synergistically with erastin and renders colon cancer cells vulnerable to ferroptosis through the HIC1-mediated inhibition of GPX4 expression, which may act as a promising therapeutic strategy. | |||
| Pair Name | Luteolin, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Up-regulation | Expression | CASP6 | hsa839 | |
| Up-regulation | Expression | CASP9 | hsa842 | |
| Down-regulation | Expression | CCNB1 | hsa891 | |
| Down-regulation | Expression | POLD1 | hsa5424 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
| Result | These findings indicate the anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cells and luteolin may be a promising candidate agent used in the treatment of gastric cancer. | |||
| Pair Name | Luteolin, SMC3 | |||
| Partner Name | SMC3 | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | BCL-xL | hsa598 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | CASP8 | hsa841 | |
| Down-regulation | Activity | NFKB1 | hsa4790 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | SOD2 | hsa6648 | |
| In Vitro Model | NCI-H23 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1547 |
| Result | The results suggest that combination of SMC3 and luteolin is an effective approach for improving the anticancer value of SMC3, which has implications in cancer prevention and therapy. | |||
| Pair Name | Luteolin, IL-24 | |||
| Partner Name | IL-24 | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Cleavage | CASP8 | hsa841 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | L-02 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_6926 |
| MHCC97-H | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_4972 | |
| Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 | |
| PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0485 | |
| Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0326 | |
| In Vivo Model | The xenograft model was established by subcutaneously injection of 4×10⁶ MHCC97-H cells into the right flank of these female BALB/c nude mice (5 weeks old). | |||
| Result | These data confirm that the synergistic mechanism of VV-IL-24 and luteolin elicits a stronger tumor growth inhibition than any single therapy. Thus, the combination of VV-IL-24 and luteolin could provide the basis for preclinical research in the treatment of liver cancer. | |||
| Pair Name | Luteolin, TNF-related apoptosis inducing ligand | |||
| Partner Name | TNF-related apoptosis inducing ligand | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP8 | hsa841 |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| In Vivo Model | A549 non-small cell lung cancer cells (2×10⁶) resuspended in 0.1mL of PBS were injected subcutaneously into athymic (nu/nu) male nude mice (5-6 weeks old). | |||
| Result | Data from this study thus provide strong in vivo evidence supporting that luteolin is a potential sensitizer for TRAIL in anticancer therapy. | |||
| Pair Name | Luteolin, Sorafenib | |||
| Partner Name | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0326 |
| SMMC-7721 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0534 | |
| Result | Sorafenib and luteolin combination synergistically kills HCC cells through JNK-mediated apoptosis, and luteolin may be an ideal candidate for increasing the activity of sorafenib in HCC therapy. | |||
| Pair Name | Luteolin, Celecoxib | |||
| Partner Name | Celecoxib | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Up-regulation | Expression | BAD | hsa572 |
| Up-regulation | Expression | BAK1 | hsa578 | |
| Up-regulation | Expression | BAX | hsa581 | |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
| SK-BR-3 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0033 | |
| In Vivo Model | MDA-MB-231 cells (2×10⁷) were inoculated subcutaneously into the right flanks of female BALB/c nude mice (6-7 weeks old) | |||
| Result | These results demonstrate the synergistic anti-tumor effect of the celecoxib and luteolin combination treatment in different four breast cancer cell lines, thus introducing the possibility of this combination as a new treatment modality. | |||
| Pair Name | Luteolin, Fluorouracil | |||
| Partner Name | Fluorouracil | |||
| Disease Info | [ICD-11: 2A00-2F9Z] | Solid tumour or cancer | Investigative | |
| Biological Phenomena | Induction-->Autophagy | |||
| Gene Regulation | Up-regulation | Expression | CASP3 | hsa836 |
| Up-regulation | Expression | CDKN1A | hsa1026 | |
| Up-regulation | Expression | DRAM1 | hsa55332 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vivo Model | Solid tumors were induced by intramuscular inoculation of 0.2 mL of ascetic fluid, containing approximately 2.5×10⁶ Ehrlich asites carcinoma cells, in the right thigh of the hind limb of each mouse | |||
| Result | Current results proved the antitumor therapeutic effects of luteolin alone or combined with 5-FU as a novel strategy for cancer therapy. | |||
| Pair Name | Luteolin, Gemcitabine | |||
| Partner Name | Gemcitabine | |||
| Disease Info | [ICD-11: 2C10.0] | Pancreatic ductal adenocarcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Down-regulation | Expression | CDH13 | hsa1012 | |
| Down-regulation | Expression | GSK3B | hsa2932 | |
| Down-regulation | Expression | KRAS | hsa3845 | |
| In Vitro Model | BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0186 |
| In Vivo Model | Male athymic nude mice were inoculated with BxPC-3 cells (1×10⁶ cells/mouse) cells | |||
| Result | Luteolin + Gem promoted apoptotic cell death in pancreatic tumor cells in vivo through inhibition of the K-ras/GSK-3β/NF-κB signaling pathway, leading to a reduction in the Bcl-2/Bax ratio, release of cytochrome c, and activation of caspase 3. | |||
| Pair Name | Luteolin, Gefitinib | |||
| Partner Name | Gefitinib | |||
| Disease Info | [ICD-11: 2C82] | Prostate cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| In Vitro Model | PC-3 | Prostate carcinoma | Homo sapiens (Human) | CVCL_0035 |
| Result | Luteolin and gefitinib regulate CCP gene expression through a common mechanism involving EGFR-associated tyrosine kinase | |||
| Pair Name | Luteolin, Imatinib | |||
| Partner Name | Imatinib | |||
| Disease Info | [ICD-11: 2A20.1] | Chronic myelogenous leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| In Vitro Model | K-562 | Blast phase chronic myelogenous leukemia | Homo sapiens (Human) | CVCL_0004 |
| Result | The combination of some flavonoids and imatinib mesylate may increase the cytotoxic effect; However, the antagonistic effect should be considered in combined use on k562 cells. | |||
| Pair Name | Luteolin, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| BEAS-2B | Healthy | Homo sapiens (Human) | CVCL_0168 | |
| In Vivo Model | To generate HCT116 xenografts in BALB/c nude mice, 3 × 106 HCT116 cells were subcutaneously injected into the left and right flanks of each mouse. | |||
| Result | The Determination of Cisplatin and Luteolin Synergistic Effect on Colorectal Cancer Cell Apoptosis and Mitochondrial Dysfunction by Fluorescence Labelling | |||
| Pair Name | Luteolin, Osimertinib | |||
| Partner Name | Osimertinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Inhibition-->Epithelial-mesenchymal transition | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Down-regulation | Expression | HGF | hsa3082 | |
| Down-regulation | Phosphorylation | MET | hsa4233 | |
| In Vitro Model | NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 |
| Result | Luteolin can synergize with osimertinib to overcome MET amplification and overactivation-induced acquired resistance to osimertinib by suppressing the HGF-MET-Akt pathway, suggesting the clinical potential of combining luteolin with osimertinib in NSCLC patients with acquired resistance. | |||
| Pair Name | Luteolin, Tamoxifen | |||
| Partner Name | Tamoxifen | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | CCNE2 | hsa9134 |
| In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
| BT-483 | Invasive breast carcinoma | Homo sapiens (Human) | CVCL_2319 | |
| BT-474 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0179 | |
| MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
| AU565 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_1074 | |
| MCF-10A | Healthy | Homo sapiens (Human) | CVCL_0598 | |
| Result | The results of this study suggest that luteolin can be used as a chemosensitiser to target the expression level of CCNE2 and that it could be a novel strategy to overcome TAM resistance in breast cancer patients. | |||
| Pair Name | Luteolin, Oxaliplatin | |||
| Partner Name | Oxaliplatin | |||
| Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
| Gene Regulation | Down-regulation | Expression | GABPA | hsa2551 |
| Down-regulation | Expression | GSTA1 | hsa2938 | |
| Down-regulation | Expression | GSTA2 | hsa2939 | |
| Down-regulation | Expression | HMOX1 | hsa3162 | |
| Down-regulation | Expression | NQO1 | hsa1728 | |
| In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
| SW620 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0547 | |
| Result | Adaptive activation of Nrf2 may contribute to the development of acquired drug-resistance and luteolin could restore sensitivity of oxaliplatin-resistant cell lines to chemotherapeutic drugs. Inhibition of the Nrf2 pathway may be the mechanism for this restored therapeutic response. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway. Molecules. 2021 Oct 26;26(21):6452. doi: 10.3390/molecules26216452. | Click |
| 2 | Combination of Lapatinib and luteolin enhances the therapeutic efficacy of Lapatinib on human breast cancer through the FOXO3a/NQO1 pathway. Biochem Biophys Res Commun. 2020 Oct 20;531(3):364-371. doi: 10.1016/j.bbrc.2020.07.049. | Click |
| 3 | Luteolin enhances erlotinib's cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines. Front Pharmacol. 2022 Sep 19;13:952169. doi: 10.3389/fphar.2022.952169. | Click |
| 4 | Luteolin potentiates low-dose oxaliplatin-induced inhibitory effects on cell proliferation in gastric cancer by inducing G2/M cell cycle arrest and apoptosis. Oncol Lett. 2022 Jan;23(1):16. doi: 10.3892/ol.2021.13134. | Click |
| 5 | Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission. Arch Biochem Biophys. 2020 Oct 15;692:108539. doi: 10.1016/j.abb.2020.108539. | Click |
| 6 | Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells. Anticancer Res. 2020 Feb;40(2):723-731. doi: 10.21873/anticanres.14003. | Click |
| 7 | Luteolin combined with low-dose paclitaxel synergistically inhibits epithelial-mesenchymal transition and induces cell apoptosis on esophageal carcinoma in vitro and in vivo. Phytother Res. 2021 Nov;35(11):6228-6240. doi: 10.1002/ptr.7267. | Click |
| 8 | Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma. Cancer Lett. 2023 Feb 1;554:216019. doi: 10.1016/j.canlet.2022.216019. | Click |
| 9 | Luteolin Shifts Oxaliplatin-Induced Cell Cycle Arrest at G₀/G₁ to Apoptosis in HCT116 Human Colorectal Carcinoma Cells. Nutrients. 2019 Apr 2;11(4):770. doi: 10.3390/nu11040770. | Click |
| 10 | Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts in Synergy with Oxaliplatin. Biomed Res Int. 2020 Feb 21;2020:9396512. doi: 10.1155/2020/9396512. | Click |
| 11 | Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression. Free Radic Biol Med. 2023 Nov 1;208:530-544. doi: 10.1016/j.freeradbiomed.2023.09.014. | Click |
| 12 | Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line. Mol Cell Biochem. 2008 Jun;313(1-2):125-32. doi: 10.1007/s11010-008-9749-x. | Click |
| 13 | Attenuating Smac mimetic compound 3-induced NF-kappaB activation by luteolin leads to synergistic cytotoxicity in cancer cells. J Cell Biochem. 2009 Dec 1;108(5):1125-31. doi: 10.1002/jcb.22346. | Click |
| 14 | Luteolin enhances the antitumor efficacy of oncolytic vaccinia virus that harbors IL-24 gene in liver cancer cells. J Clin Lab Anal. 2021 Mar;35(3):e23677. doi: 10.1002/jcla.23677. | Click |
| 15 | Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem Biophys Res Commun. 2012 Jan 13;417(2):842-6. doi: 10.1016/j.bbrc.2011.12.055. | Click |
| 16 | Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation. Oncol Lett. 2018 Jul;16(1):648-653. doi: 10.3892/ol.2018.8640. | Click |
| 17 | Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells. Tumour Biol. 2015 Aug;36(8):6349-59. doi: 10.1007/s13277-015-3322-5. | Click |
| 18 | Luteolin and 5-flurouracil act synergistically to induce cellular weapons in experimentally induced Solid Ehrlich Carcinoma: Realistic role of P53; a guardian fights in a cellular battle. Chem Biol Interact. 2019 Sep 1;310:108740. doi: 10.1016/j.cbi.2019.108740. | Click |
| 19 | Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model. Pancreas. 2015 Jan;44(1):144-51. doi: 10.1097/MPA.0000000000000215. | Click |
| 20 | Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells. J Steroid Biochem Mol Biol. 2010 Oct;122(4):219-31. doi: 10.1016/j.jsbmb.2010.06.006. | Click |
| 21 | Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method. Balkan Med J. 2019 Feb 28;36(2):96-105. doi: 10.4274/balkanmedj.galenos.2018.2017.1244. | Click |
| 22 | Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. Mol Med Rep. 2019 Jul;20(1):728-734. doi: 10.3892/mmr.2019.10296. | Click |
| 23 | Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway. Am J Cancer Res. 2023;13(9):4145-4162. | Click |
| 24 | Luteolin sensitises drug-resistant human breast cancer cells to tamoxifen via the inhibition of cyclin E2 expression. Food Chem. 2013 Nov 15;141(2):1553-61. doi: 10.1016/j.foodchem.2013.04.077. | Click |
| 25 | Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Asian Pac J Cancer Prev. 2014;15(6):2911-6. doi: 10.7314/apjcp.2014.15.6.2911. | Click |
